Trial Profile
A study of AGS-004 in combination with vorinostat for the treatment of human immunodeficiency virus (HIV)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2018
Price :
$35
*
At a glance
- Drugs AGS 004 (Primary) ; Vorinostat
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2018 According to an Argos Therapeutics media release, initial data from the trial is expected during the second half of 2018.
- 29 Jul 2017 New trial record